Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer

Purpose Several factors have been identified that predict positive fluorine-18-fluoromethylcholine (18F-FCH) PET/CT result in patients with prostate cancer undergoing PET/CT for biochemical failure. Among these factors, prostate-specific antigen (PSA) is the single factor most consistently associated with the prediction of positive 18F-FCH PET/CT. In this study, we wished to confirm this finding and expand it in a large series of patients. Patients and methods We retrospectively analyzed 192 patients with prostate cancer who were recruited from the Nuclear Medicine Department of the Sant’Andrea Hospital of La Spezia, Italy, from March 2013 to March 2018 and who underwent 18F-FCH PET/CT owing to biochemical failure after radical prostatectomy. Results Median trigger PSA was 2.57 ng/ml. The overall positive detection rate of 18F-FCH PET/CT was 60.9%. The percent of positive scans was 30.5% for PSA less than 1 ng/ml, 59.4% (38/64) for PSA between 1 and 5 ng/ml, and 88.4% for PSA greater than 5 ng/ml (P<0.001). On univariate regression analysis, high PSA levels, biochemical failure during antiandrogenic therapy at the time of PET/CT, and older age significantly (P<0.05) predicted positive 18F-FCH PET/CT result. On multivariate regression analysis, only high PSA levels and biochemical failure during antiandrogenic therapy maintained the statistical significance (P<0.05). However, when the analysis was restricted to patients with PSA less than 1 ng/ml, PSA lost the statistical significance. Receiver operating characteristic analysis revealed an area under the curve of 0.795. The PSA cutoff value that best distinguished PET/CT-positive from PET/CT-negative patients was 2.57 ng/ml. Sensitivity and specificity at this PSA value were 66.7 and 76.0%, respectively. Conclusion This study confirms that PSA robustly predicts positive PET/CT result with radiolabeled choline. Unfortunately, this study also confirms the limited sensitivity of 18F-FCH PET/CT for PSA less than 1 ng/ml, which currently represents the weakest point of the technique.

[1]  R. Boellaard,et al.  Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.

[2]  A. Agostini,et al.  Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml , 2018, Nuclear medicine communications.

[3]  A. Ciarmiello,et al.  11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients. , 2017, Current radiopharmaceuticals.

[4]  M. Scorsetti,et al.  11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer , 2017, Cancer investigation.

[5]  A. Ciarmiello,et al.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Picchio,et al.  Toxicity and efficacy of salvage carbon 11‐choline positron emission tomography/computed tomography‐guided radiation therapy in patients with lymph node recurrence of prostate cancer , 2017, BJU international.

[7]  M. Picchio,et al.  New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. , 2016, European urology.

[8]  M. Schwaiger,et al.  Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  S. Fanti,et al.  11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  M. Picchio,et al.  Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes? , 2015, The Journal of Nuclear Medicine.

[11]  K. Partanen,et al.  PET/CT Dose Planning for Volumetric Modulated Arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer Patients. , 2015, Current radiopharmaceuticals.

[12]  F. Montorsi,et al.  Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. , 2015, European urology.

[13]  G. Mariani,et al.  Gleason Score at Diagnosis Predicts the Rate of Detection of 18F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients , 2015, The Journal of Nuclear Medicine.

[14]  E. Scarpi,et al.  18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  A. Buck,et al.  Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  M. Marzola,et al.  Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Mohsen Beheshti,et al.  Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics , 2013, The Journal of Nuclear Medicine.

[18]  M. Picchio,et al.  Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy: Correlation With Trigger PSA, PSA Velocity, PSA Doubling Time, and Metastatic Distribution , 2013, Clinical nuclear medicine.

[19]  F. Montorsi,et al.  [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. , 2013, The Journal of urology.

[20]  A. Pupi,et al.  Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment , 2013, Journal of Cancer Research and Clinical Oncology.

[21]  P. Cumming,et al.  Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  F. Calabria,et al.  Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  M. Schwaiger,et al.  Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  F. Montorsi,et al.  [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. , 2010, The Journal of urology.

[25]  F. Montorsi,et al.  PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  P. Waldenberger,et al.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.

[27]  V. Ambrosini,et al.  Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  V. Bettinardi,et al.  Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  C. Nanni,et al.  Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy , 2009, Journal of Nuclear Medicine.

[30]  H. Zaidi,et al.  Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence , 2008, Nuklearmedizin.

[31]  M. Schwaiger,et al.  The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  A. Dirisamer,et al.  Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml? , 2005, Molecular Imaging and Biology.

[33]  F Fazio,et al.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. , 2003, The Journal of urology.